Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Recruitment status was Recruiting
Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.
This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.
The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART|
- pregnancy rate [ Time Frame: 2weeks ] [ Designated as safety issue: Yes ]
- ovarian stimulation [ Time Frame: 10days ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2008|
|Estimated Study Completion Date:||January 2009|
|Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
GnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation
These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
Active Comparator: 2
GnRH agonist, suprefact, stimulation with a standard long protocol
GnRH agonist, standard protocol
Please refer to this study by its ClinicalTrials.gov identifier: NCT00823602
|Contact: razieh firouzabadi, MD||8247085 ext +firstname.lastname@example.org|
|Contact: shahnaz Ahmadi, MD||9173717981 ext +98||AHMADISHAHNAZ2005@yahoo.com|
|Iran, Islamic Republic of|
|Yazd Research and Clinical Center For Infertility||Recruiting|
|Yazd, Iran, Islamic Republic of|
|Contact: razieh firouzabadi, MD 8247085 ext +98351 email@example.com|
|Contact: shahnaz Ahmadi, MD 9173717981 ext +98 AHMADISHAHNAZ2005@yahoo.com|
|Principal Investigator: shahnaz ahmadi, MD|
|Study Chair:||razieh firouzabadi, MD||Yazd Research & Clinical Center for Infertility|